Welcome to our dedicated page for Pharmadrug news (Ticker: LMLLF), a resource for investors and traders seeking the latest updates and insights on Pharmadrug stock.
PharmaDrug Inc. (LMLLF) provides investors and industry stakeholders with essential updates through this centralized news repository. Our curated collection focuses on material developments in biosynthetic pharmaceutical manufacturing, clinical research advancements, and strategic partnerships within the specialty pharmaceuticals sector.
Access verified corporate disclosures including regulatory filings, manufacturing process patents, and subsidiary developments. Key coverage areas include GMP-compliant production milestones, natural medicine reformulation progress, and controlled substance research updates aligned with harm reduction initiatives.
This resource serves as a definitive source for tracking PharmaDrug's progress in pharmaceutical-grade substance development. Users will find official communications regarding technology licensing agreements, clinical trial authorizations, and intellectual property expansions within the biosynthetic chemistry domain.
Bookmark this page for direct access to original press releases and SEC filings. For comprehensive understanding of PharmaDrug's position in specialty pharmaceuticals, we recommend reviewing updates regularly and consulting official regulatory documents for complete context.
PharmaDrug Inc. announces the appointment of Zalman Goldman to its board of directors, with a background in addiction and recovery, to advance the company's mission in drug research and commercialization. Concurrently, Nickolai Vassev resigns from the board. Mr. Goldman brings valuable experience to the company, receiving 500,000 stock options as part of his appointment.
PharmaDrug's Sairiyo Therapeutics has finished the clinical and regulatory package for a Phase 1 study of their reformulated cepharanthine in Australia. This patented drug, PD-001, aims to treat infectious diseases and oncology. Sairiyo will conduct the study in Australia to benefit from drug development incentives, planning to submit an Investigational New Drug application to the FDA afterward.
FAQ
What is the current stock price of Pharmadrug (LMLLF)?
What is the market cap of Pharmadrug (LMLLF)?
